GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (NAS:CHRS) » Definitions » Shiller PE Ratio

Coherus BioSciences (Coherus BioSciences) Shiller PE Ratio : (As of Apr. 27, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Coherus BioSciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Coherus BioSciences Shiller PE Ratio Historical Data

The historical data trend for Coherus BioSciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus BioSciences Shiller PE Ratio Chart

Coherus BioSciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Coherus BioSciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Coherus BioSciences's Shiller PE Ratio

For the Biotechnology subindustry, Coherus BioSciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coherus BioSciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus BioSciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Coherus BioSciences's Shiller PE Ratio falls into.



Coherus BioSciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Coherus BioSciences's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Coherus BioSciences's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.74/129.4194*129.4194
=-0.740

Current CPI (Dec. 2023) = 129.4194.

Coherus BioSciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -1.392 99.695 -1.807
201406 -1.380 100.560 -1.776
201409 -0.246 100.428 -0.317
201412 -1.470 99.070 -1.920
201503 -1.220 99.621 -1.585
201506 -1.560 100.684 -2.005
201509 -1.860 100.392 -2.398
201512 -1.350 99.792 -1.751
201603 -1.670 100.470 -2.151
201606 -1.720 101.688 -2.189
201609 1.670 101.861 2.122
201612 -1.710 101.863 -2.173
201703 -1.540 102.862 -1.938
201706 -1.080 103.349 -1.352
201709 -1.090 104.136 -1.355
201712 -0.840 104.011 -1.045
201803 -0.740 105.290 -0.910
201806 -0.680 106.317 -0.828
201809 -0.870 106.507 -1.057
201812 -0.920 105.998 -1.123
201903 -0.290 107.251 -0.350
201906 0.320 108.070 0.383
201909 0.630 108.329 0.753
201912 0.530 108.420 0.633
202003 0.480 108.902 0.570
202006 0.700 108.767 0.833
202009 0.330 109.815 0.389
202012 0.120 109.897 0.141
202103 -2.370 111.754 -2.745
202106 -0.400 114.631 -0.452
202109 -0.490 115.734 -0.548
202112 -0.600 117.630 -0.660
202203 -1.240 121.301 -1.323
202206 -0.650 125.017 -0.673
202209 -1.110 125.227 -1.147
202212 -0.760 125.222 -0.785
202303 -0.960 127.348 -0.976
202306 -0.490 128.729 -0.493
202309 -0.410 129.860 -0.409
202312 -0.740 129.419 -0.740

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Coherus BioSciences  (NAS:CHRS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Coherus BioSciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Coherus BioSciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Coherus BioSciences (Coherus BioSciences) Business Description

Traded in Other Exchanges
Address
333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.
Executives
Dennis M Lanfear director, officer: President and CEO C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Michael Lee Ryan director C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Mcdavid Stilwell officer: Chief Financial Officer C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Bryan J Mcmichael officer: See Remarks C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, REDWOOD CITY CA 94065
Paul Reider officer: Chief Commercial Officer C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jill O'donnell-tormey director C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Charles W. Newton director 46 FREDRICK AVENUE, ATHERTON CA 94027
Lee Nisley Newcomer director 264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Vladimir Vexler officer: Chief Scientific Officer 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Vincent R Anicetti officer: Chief, Quality & Compliance COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065
Jean-frederic Viret officer: Chief Financial Officer ANESIVA, INC., 650 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Mark Stolper director 150 COTNER AVENUE, LOS ANGELES CA 90025
Alan C Mendelson director ALAN C MENDELSON, 135 COMMONWEALTH DR, MENLO PARK CA 94025
Kimberly Jo Tzoumakas director 1170 FAIRFAX STREET, BIRMINGHAM MI 48009